ONC201 Publications

onc201

Role of ClpP in the Anti-cancer Effects of Imipridone ONC201 and ONC206

American Association for Cancer Research (AACR) Annual Meeting; April 14-19, 2023

Lee, Maranto, Foster, et al

onc201

ACTION: A randomized phase 3 study of dordaviprone (ONC201) in patients with newly diagnosed H3 K27M-mutant diffuse glioma

American Association for Cancer Research (AACR) Annual Meeting; April 14-19, 2023 –Orlando, FL

Isabel Arrillaga-Romany

onc201

Safety of ONC201 administered two consecutive days per week in pediatric H3 K27M-mutant glioma patients

2021 SNO Annual Meeting Abstract CTNI-36

Sharon L. Gardner, M.D., New York University School of Medicine

onc201

Clinical efficacy of ONC201 in recurrent H3 K27M-mutant diffuse midline glioma patients

2021 SNO Annual Conference

Isabel Arrillaga-Romany, M.D., Ph. D., Massachusetts General Hospital

onc201

Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors

Neuro Oncol. 2021 PMID: 32830856

He Y, Li J, Koga T, et al.

onc201

A Bayesian machine learning approach for drug target identification using diverse data types

Nat Commun. 2019 PMID: 31745082

Madhukar NS, Khade PK, Huang L, et al.

onc201

Biological activity of weekly ONC201 in adult recurrent glioblastoma patients

Neuro Oncol. 2020 PMID: 31702782

Arrillaga-Romany I, Odia Y, Prabhu VV, et al.

onc201

Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201

J Neurooncol. 2019 PMID: 31456142

Chi AS, Tarapore RS, Hall MD, et al.

onc201

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

J Immunother Cancer. 2019 PMID: 31118108

Stein MN, Malhotra J, Tarapore RS, et al.

onc201

Dopamine receptor D5 is a modulator of tumor response to dopamine receptor D2 antagonism

Clin Cancer Res. 2019 PMID: 30559168

Prabhu VV, Madhukar NS, Gilvary C, et al.